File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis

TitlePrognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis
Authors
KeywordsAmyotrophic Lateral Sclerosis
Database
Motor Neuron Disease
Prognostic Modelling
Riluzole
Issue Date2002
Citation
Amyotrophic Lateral Sclerosis And Other Motor Neuron Disorders, 2002, v. 3 n. 1, p. 15-21 How to Cite?
AbstractBackground: Amyotrophic lateral sclerosis (ALS) is a disease with a widely varying prognosis. The majority of patients survive about 3 years, but a significant number survive for 10 years or more, leading to problems in clinical trial design. Objective: To demonstrate that simple clinical variables can be used to construct a robust predictive model for survival, and to assess the effect of a known treatment within this model. Methods: We carried out a retrospective multivariate modelling of a database of 841 patients with ALS seen over a 10-year period in a specialist motor neuron disorders clinic. The use of riluzole was tested as a prognostic factor within the model. Results: A prognostic score generated from one cohort of patients predicted survival for a second cohort of patients (r 2= 0.78). Prognostic variables included site of onset, age of onset, time from symptom onset to diagnosis, and El Escorial category at presentation. Riluzole therapy was an independently significant prognostic factor (relative risk of death 0.48, P<0.0001, model X 2 297, P<0.0001). Conclusions: Clinical databases can be used to generate multivariate prognostic models in ALS. Such models could be used to predict survival, to improve criteria for matching of patients in future clinical trials, and to test the impact of interventions.
Persistent Identifierhttp://hdl.handle.net/10722/175854
ISSN
2005 Impact Factor: 1.718
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTurner, MRen_US
dc.contributor.authorBakker, Men_US
dc.contributor.authorSham, Pen_US
dc.contributor.authorShaw, CEen_US
dc.contributor.authorLeigh, PNen_US
dc.contributor.authorAlChalabi, Aen_US
dc.date.accessioned2012-11-26T09:01:50Z-
dc.date.available2012-11-26T09:01:50Z-
dc.date.issued2002en_US
dc.identifier.citationAmyotrophic Lateral Sclerosis And Other Motor Neuron Disorders, 2002, v. 3 n. 1, p. 15-21en_US
dc.identifier.issn1466-0822en_US
dc.identifier.urihttp://hdl.handle.net/10722/175854-
dc.description.abstractBackground: Amyotrophic lateral sclerosis (ALS) is a disease with a widely varying prognosis. The majority of patients survive about 3 years, but a significant number survive for 10 years or more, leading to problems in clinical trial design. Objective: To demonstrate that simple clinical variables can be used to construct a robust predictive model for survival, and to assess the effect of a known treatment within this model. Methods: We carried out a retrospective multivariate modelling of a database of 841 patients with ALS seen over a 10-year period in a specialist motor neuron disorders clinic. The use of riluzole was tested as a prognostic factor within the model. Results: A prognostic score generated from one cohort of patients predicted survival for a second cohort of patients (r 2= 0.78). Prognostic variables included site of onset, age of onset, time from symptom onset to diagnosis, and El Escorial category at presentation. Riluzole therapy was an independently significant prognostic factor (relative risk of death 0.48, P<0.0001, model X 2 297, P<0.0001). Conclusions: Clinical databases can be used to generate multivariate prognostic models in ALS. Such models could be used to predict survival, to improve criteria for matching of patients in future clinical trials, and to test the impact of interventions.en_US
dc.languageengen_US
dc.relation.ispartofAmyotrophic Lateral Sclerosis and Other Motor Neuron Disordersen_US
dc.subjectAmyotrophic Lateral Sclerosisen_US
dc.subjectDatabaseen_US
dc.subjectMotor Neuron Diseaseen_US
dc.subjectPrognostic Modellingen_US
dc.subjectRiluzoleen_US
dc.titlePrognostic modelling of therapeutic interventions in amyotrophic lateral sclerosisen_US
dc.typeArticleen_US
dc.identifier.emailSham, P: pcsham@hku.hken_US
dc.identifier.authoritySham, P=rp00459en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1080/146608202317576499en_US
dc.identifier.pmid12061944-
dc.identifier.scopuseid_2-s2.0-0035991266en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0035991266&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume3en_US
dc.identifier.issue1en_US
dc.identifier.spage15en_US
dc.identifier.epage21en_US
dc.identifier.isiWOS:000176301500004-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridTurner, MR=7403215612en_US
dc.identifier.scopusauthoridBakker, M=7101722373en_US
dc.identifier.scopusauthoridSham, P=34573429300en_US
dc.identifier.scopusauthoridShaw, CE=35370282000en_US
dc.identifier.scopusauthoridLeigh, PN=26643325600en_US
dc.identifier.scopusauthoridAlChalabi, A=7003751621en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats